Premium
Expression of MAGE genes in osteosarcoma
Author(s) -
Sudo Takao,
Kuramoto Terukazu,
Komiya Setsuro,
Inoue Akio,
Itoh Kyogo
Publication year - 1997
Publication title -
journal of orthopaedic research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.041
H-Index - 155
eISSN - 1554-527X
pISSN - 0736-0266
DOI - 10.1002/jor.1100150119
Subject(s) - major histocompatibility complex , gene , biology , histocompatibility , antigen , cytotoxic t cell , microbiology and biotechnology , cell culture , reverse transcription polymerase chain reaction , messenger rna , cancer research , human leukocyte antigen , immunology , genetics , in vitro
Expression of MAGE genes that encode tumor‐rejection antigens recognized by cytotoxic T lymphocytes with major histocompatibility complex class‐I antigens was investigated in human osteosarcomas (20 cell lines and eight fresh tumor tissues). MAGE‐1,2,3,4, and 6 genes were expressed at the mRNA level in 11(52.4%), 10(47.6%), 10(47.6%), one (4.8%) and 10 (47.6%) of 21 tumor cell lines, respectively, and in five (62.5%), six (75%), five (62.5%), one (12.5%) and five (62.5%) of eight fresh tumor tissues as determined by the reverse transcription‐polymerase chain reaction method. MAGE‐1 or 4 protein was detected by immunoblot analysis in eight of 11 or one of one tumor cell lines, respectively where it was expressed at the mRNA level. Major histocompatibility complex class‐I antigens were expressed 19 of 21 tumor cell lines. These results suggest that MAGE tumor‐rejection antigens are expressed in substantial numbers of osteosarcomas in a major histocompatibility class‐I‐restricted manner.